|
|
|
|
| LEADER |
01339 am a22002053u 4500 |
| 001 |
112275 |
| 042 |
|
|
|a dc
|
| 100 |
1 |
0 |
|a McCarroll, Steven A
|e author
|
| 100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
|e contributor
|
| 100 |
1 |
0 |
|a McGovern Institute for Brain Research at MIT
|e contributor
|
| 100 |
1 |
0 |
|a McCarroll, Steven A
|e contributor
|
| 100 |
1 |
0 |
|a Feng, Guoping
|e contributor
|
| 700 |
1 |
0 |
|a Feng, Guoping
|e author
|
| 700 |
1 |
0 |
|a Hyman, Steven E
|e author
|
| 245 |
0 |
0 |
|a Genome-scale neurogenetics: methodology and meaning
|
| 260 |
|
|
|b Nature Publishing Group,
|c 2017-11-22T15:24:18Z.
|
| 856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/112275
|
| 520 |
|
|
|a Genetic analysis is currently offering glimpses into molecular mechanisms underlying such neuropsychiatric disorders as schizophrenia, bipolar disorder and autism. After years of frustration, success in identifying disease-associated DNA sequence variation has followed from new genomic technologies, new genome data resources, and global collaborations that could achieve the scale necessary to find the genes underlying highly polygenic disorders. Here we describe early results from genome-scale studies of large numbers of subjects and the emerging significance of these results for neurobiology.
|
| 655 |
7 |
|
|a Article
|
| 773 |
|
|
|t Nature Neuroscience
|
